Are Sanofi India latest results good or bad?

Sanofi India has reported its financial results for the quarter ending March 2025, showcasing notable performance across several key metrics. The company's Profit Before Tax (PBT), excluding other income, reached Rs 162.00 crore, reflecting a significant growth compared to the average PBT of Rs 88.25 crore over the previous four quarters. This indicates a strong near-term outlook for profitability.
The operating cash flow for Sanofi India also reached its highest level in three years, totaling Rs 461.70 crore, which suggests an increase in cash revenues from business operations. Additionally, net sales hit a five-quarter high of Rs 535.90 crore, while the operating profit (PBDIT) stood at Rs 171.90 crore, demonstrating improved operational efficiency with an operating profit margin of 32.08%.

However, the company is facing some challenges, including a declining Debtors Turnover Ratio, which fell to 8.75 times, indicating a slower pace in settling debts. Furthermore, the annual dividend per share has decreased to Rs 117.00, marking the lowest level in five years, which may suggest a reduction in shareholder returns.

Overall, the financial data indicates that Sanofi India has experienced a positive operational performance, while also highlighting areas that may require attention. Additionally, the company saw an adjustment in its evaluation based on these results.